Cargando…
A case of aggressive systemic mastocytosis with bulky lymphadenopathy showing response to midostaurin
Management of systemic mastocytosis is an emerging challenge which requires a multidisciplinary diagnostic approach and personalized treatment strategy. Midostaurin can rapidly reduce the disease burden, also in cladribine refractory cases.
Autores principales: | Sciumè, Mariarita, Serpenti, Fabio, Muratori, Simona, Pravettoni, Valerio, Ulivieri, Fabio Massimo, Croci, Giorgio Alberto, Migliorini, Anna Chiara, Esposito, Andrea, Goldaniga, Maria Cecilia, Saporiti, Giorgia Natascia, Galassi, Giulia, Baldini, Luca, Onida, Francesco, Grifoni, Federica Irene |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869399/ https://www.ncbi.nlm.nih.gov/pubmed/33598282 http://dx.doi.org/10.1002/ccr3.3717 |
Ejemplares similares
-
Viral Infections in HSCT: Detection, Monitoring, Clinical Management, and Immunologic Implications
por: Annaloro, Claudio, et al.
Publicado: (2021) -
Case Report: Evolution of KIT D816V-Positive Systemic Mastocytosis to Myeloid Neoplasm With PDGFRA Rearrangement Responsive to Imatinib
por: Sciumè, Mariarita, et al.
Publicado: (2021) -
Treatment of Advanced Systemic Mastocytosis with Midostaurin: Practical Guidance for Optimal Therapy and Management
por: Papayannidis, Cristina, et al.
Publicado: (2022) -
Clinical potential of midostaurin in advanced systemic mastocytosis
por: Chandesris, Marie Olivia, et al.
Publicado: (2017) -
Real-World Efficacy of Midostaurin in Aggressive Systemic Mastocytosis
por: Szudy-Szczyrek, Aneta, et al.
Publicado: (2021)